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Abstract
Introduction—National and International Hematology/Oncology Practice Guidelines 
recommend testing for the BCR-ABL mutation for definitive diagnosis of chronic myeloid 
leukemia (CML) to allow for appropriate treatment with a Tyrosine Kinase Inhibitor (TKI). The 
purpose of our study was to describe population-based testing and treatment practice 
characteristics for patients diagnosed with CML.
Methods—We analyzed cases of CML using 2011 data from 10 state registries which are part of 
the Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries. 
We describe completeness of testing for the BCR-ABL gene and availability of outpatient 
treatment with TKIs and associated characteristics.
Results—A total of 685 cases of CML were identified; 55% (374) had a documented BCR-ABL 
gene test with 96% (360) of these being positive for the BCR-ABL gene and the remaining 4% 
(14) either testing negative or had a missing result. Registries were able to identify the use of TKIs 
in 54% (369) of patients, though only 43% (296) had a corresponding BCR-ABL gene test 
documented. One state registry reported a significantly lower percentage of patients being tested 
for the BCR-ABL gene (25%) and receiving TKI treatment (21%). Limiting analysis to CML case 
reports from the remaining nine CER registries, 78% (305) patients had a documented BCR-ABL 
gene test and 79% (308) had documented treatment with a TKI. Receipt of testing or treatment for 
these nine states did not vary by sex, race, ethnicity, census tract poverty level, census tract 
urbanization, or insurance status; BCR-ABL testing varied by state of residence and BCR-ABL 
testing and TKI therapy occurred less often with increasing age (OR: 0.97, 95%CI: 0.95–0.99; 
OR: 0.97, 95%CI: 0.96–0.99 respectively).
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Conclusions—Collection of detailed CML data vary significantly by states. A majority of the 
case patients had appropriate testing for the BCR-ABL gene and treatment with tyrosine kinase 
inhibitors. However, BCR-ABL testing and TKI treatment decreased with increasing age. Further 
research is needed to understand CML coding, testing, and treatment disparities.
Keywords
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Introduction
Chronic Myeloid Leukemia (CML) is a neoplasm resulting from uncontrolled growth of 
bone marrow stem cells of the myeloid cell line. Most people found to have an elevated 
neutrophil count will not have CML. Even though a presumptive diagnosis can be made 
based on clinical features and routine blood work, a definitive diagnosis of CML requires 
either the demonstration of the t(9;22) Philadelphia chromosome translocation (by 
fluorescent in situ hybridization or FISH), or BCR-ABL1 fusion gene (qRT-PCR).1, 2 The 
BCR-ABL gene is a result of a chromosomal translocation between Chromosome 9 and 22 
resulting in an overproduction of a tyrosine kinase protein ultimately leading to uncontrolled 
cell proliferation and lack of normal cell death. Tyrosine Kinase Inhibitors, or TKIs, bind to 
the active site of the BCR-ABL protein (a tyrosine kinase) stopping cell growth and leading 
to apoptosis (natural cell death). Verifying the presence of the Philadelphia Chromosome 
became even more important with the advent of TKIs that target the abnormal kinase 
proteins. Imatinib (Gleevec) was the first TKI developed in the late 1990s and first approved 
by the FDA for first line use for CML in 2002.3 By 2009, national and international 
hematology practice guidelines clearly recommended both BCR-ABL gene testing for 
accurate diagnosis of CML and prompt treatment with a tyrosine kinase inhibitor such as 
Imatinib, Dasatinib (Srpycel), or Nilotinib (Tasigna).4, 5, 6 However, population-based 
evaluation of BCR-ABL testing and treatments received by CML patients is still limited.
The goals of our study included assessing the ability of state registries to collect treatment 
data from a variety medical care settings, including non-hospital outpatient settings; provide 
a population-based, real-world look at testing and treatment practices outside of randomized 
clinical trials (RCT); and evaluate patient characteristics that may affect BCR-ABL gene 
testing and TKI therapy, such as demographic, socioeconomic status (SES), and clinical 
features such as comorbidities.
Methods
To capture unique population level testing and treatment data, the Centers for Disease 
Control and Prevention’s (CDC’s), National Program of Cancer Registries (NPCR) applied 
for and was granted federal funding to Enhance Cancer Registry Data for Comparative 
Effectiveness Research (CER).7 Comparative effectiveness research provides information for 
practitioners and patients alike either by describing benefits and harms of different treatment 
options and strategies currently available, or by performing new studies to evaluate 
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effectiveness of treatment in “real world” settings.8 Eight state cancer registries (Alaska, 
Colorado, Idaho, Louisiana, North Carolina, New Hampshire, Rhode Island, Texas) and 
metropolitan centers in two states (Sacramento Area in California and the Miami-Dade, 
Orlando, and Tampa areas in Florida) were selected through a competitive process, as 
Specialized Registries for the collection of CER. This NPCR CER population represents 
approximately 27% of the United States population and were chosen to ensure racial/ethnic 
diversity. The National Program of Cancer Registries Cancer Surveillance System was 
granted approval for collection of CER data from CDC’s Institutional Review Board (IRB) 
and from the Office of Management and Budget as collection of additional data items and 
submission of de-identified information were authorized by existing cancer reporting laws 
and regulations in participating states. Individual states also received state level IRB 
approval or were considered exempt as the collection of enhanced registry data was 
considered public health surveillance. All additional data items were collected through re-
abstraction of the patient medical record or direct data linkages with medical care facilities; 
no patients were contacted for this project.
CER specific data, including detailed testing and treatment information, were collected from 
medical care providers for all CML diagnoses in 2011, as well as for cancers of the colon, 
rectum, and breast. Registries built upon routine NAACCR abstracts adding CER specific 
data typically through one of three methods: (1) onsite visits to hospital, hospital based and 
non-hospital hematology/oncology practice groups and private practice physician offices, (2) 
obtained hard copies or secured remote access from these facilities, (3) or direct 
transmission of data by the facility. A detailed description of NPCR’s CER methods and 
additional data elements collected has been previously described.9 Our study includes all 
patients diagnosed with either BCR-ABL+ CML (International Classification of Disease 
(ICD)-O3 Histology code 9875) and CML NOS (ICD-O3 Histology code 9863) a code 
generally used as a provisional diagnosis when a myelogenous leukemia is identified prior to 
genetic studies being completed.10 Type of BCR-ABL gene test was collected, including 
cytogenetic testing, fluorescence in situ hybridization (FISH), qualitative reverse 
transcriptase polymerase chain reaction (RT-PCR), and quantitative RT-PCR. Date the test 
was performed and results were recorded; if no date was found, a date flag was required to 
indicate the reason (not found, not performed, etc.). Through a combination of testing 
results, dates, and date flags we grouped patients into four categories: 1) BCR-ABL gene 
test performed, with positive result; 2) BCR-ABL gene not tested or not applicable; 3) 
unknown if BCR-ABL gene testing occurred; and 4)BCR-ABL gene test performed, either 
no result recorded or negative result. No information was collected to understand when 
genetic testing was deemed not applicable or not performed. Coding options were not 
sensitive enough to differentiate between those tested with no result recorded or a negative 
result.
The project collected up to six first course chemotherapy agents for each patient using the 
standardized National Cancer Institute numeric identifier, or NSC number, created when a 
medication is undergoing therapeutic development testing. Registrars could also record 
whether there was indication in the medical record of “Chemotherapy not planned” or 
“Unknown if chemotherapy planned or not required”. Additional standard NPCR variables 
such as RxDateChemo (date of initiation of chemotherapy) collected from hospitals with a 
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Commission on Cancer Approved Cancer Program (CoC) were also cross-referenced to 
CER specific chemotherapy fields. A patient was categorized as receiving a tyrosine kinase 
inhibitor if one of the agents recorded as part of first course therapy included Imatinib, 
Disatinib, or Nilotinib.
Insurance status at time of diagnosis was collected and additional socio-economic status 
(SES) measures, including census tract poverty and urbanization, were based on a patient’s 
address at time of diagnosis. Insurance status was grouped into categories of no insurance, 
private insurance (includes Medicare with private supplement), Medicare, Medicaid/Other 
Public (Veterans Affairs, Tricare, Indian Health Service), insurance not otherwise specified, 
and unknown/missing insurance. Census tract poverty and urbanization were determined 
based on census tract associated with patient address at time of diagnosis and SES measure 
cut offs were selected to be consistent with current literature.11, 12 Impoverished 
communities were selected as those where over 20% of the population in the census tract fell 
below the poverty line.13 Census tract urbanization was defined as urban if all areas in the 
census tract were considered in an urban setting, rural if all areas in the census tract were 
considered in a rural setting, and mixed if a combination of rural and urban areas in a census 
tract.14
Attempts were also made to collect patient level characteristics, such as tobacco use and 
comorbid conditions, which were obtained through medical records and through state 
registry linkages with hospital discharge files and other data sets. We combined available 
information on patients’ history of smoking cigarettes, use of other smoking tobacco (pipes, 
etc.), chewing tobacco, and other tobacco into one variable to indicate current tobacco use, 
former tobacco use (quit for more than one year), no tobacco use, and unknown tobacco use 
history. Comorbidities were re-abstracted using ICD-9 coding and were placed into one of 
three categories for later analysis: 1) comorbidity based on the Charlson comorbidity scale 
indicating more severe comorbidity that may affect treatment options (e.g. history of cardiac 
or hepatic disease), 2) Non-Charlson comorbidity considered less severe in nature, 3) no 
comorbidity / unknown as these two codes could not be differentiated.15, 16
Analyses were conducted using the enhanced CER dataset with updated vital status as 
submitted by the 10 Specialized Registry sites to the NPCR Cancer Surveillance System in 
November 2014. We used SAS version 9.3 (SAS Institute, Cary, NC) to perform a 
descriptive analysis assessing factors associated with BCR-ABL gene testing and TKI 
treatment for CML patients. Bivariate analysis was performed using Pearson’s Chi Square 
and multi-variable analysis was completed using multi-variable logistic regression analysis. 
Models were developed for the dependent variable BCR-ABL testing (whether a test was 
recorded or not) and a Tyrosine Kinase Inhibitor (recorded or not recorded) in the patient 
record.
Results
Of 805 CML cases in the NPCR CER dataset, we excluded 92 cases reported after the 
completion of the project, nine autopsy only cases, one case of unknown age, three CML 
NOS cases that died within an unknown time from diagnosis and 15 that died within the first 
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seven days of diagnosis. This window of seven days was selected since BCR-ABL gene 
testing can range from 3–7 days, a necessity for definitive diagnosis and to confirm 
candidacy for TKI therapy. Our final sample contains 685 cases of CML. Of them, 51% 
(352) were recorded as having BCR-ABL positive CML; the remaining 49% (333) were 
recorded as CML NOS.
Patient demographic information is displayed in Table 1. A slight majority of patients 
diagnosed with CML were males (55% [376]). Median age was 58 years with a range from 
5–99 years. Race/ethnicity data were available for 677 patients of which 64% (440) were 
Non-Hispanic White, 14% (97) Non-Hispanic Black, 2% (14) Non-Hispanic Other, and 18% 
(126) Hispanic all races. Primary payer information at diagnosis showed a majority (91% 
[626]) had documentation of medical insurance; 41% (282) had private insurance, 5% (32) 
had insurance not otherwise specified, 13% (90) Medicaid or other government sponsored 
(Tricare/Military, Veterans Affairs, Indian Health Service), 23% (154) Medicare, 10% (68) 
were uninsured at diagnosis, and the remaining 9% (59) had unknown/missing insurance 
status. The majority of patients (57% [391]) lived in urban areas as defined by the US 
Census Bureau, with most of the remaining living in census tracts where the population lived 
in a mixed urban or rural setting (34% [235]) or purely rural census tracts (8% [55]); four 
were missing census tract data. Eighty-one percent (555) of patients lived in census tracts 
where less than 20% of the families in the census tract had income below the poverty line in 
the last 12 months. Distribution of diagnoses in the 10 CER sites are presented in Table 1. 
Nearly half of the cases came from State A (43% [292]) with States B-E contributing the 
bulk of the remaining cases (46% [313]), although age-adjusted incidence rates in these 
states based on 2010 population were similar ranging between 1.6–2.2 per 100,000.17
Patient characteristics, including tobacco use and comorbidities, can affect the risk of 
developing CML and/or the ability to receive various types of treatment including 
TKIs.18, 19 Data collected from medical documentation showed forty percent (273) of 
patients reported never using any type of tobacco product, 17% (119) were former tobacco 
users, and only 10% (66) were current users. One third (227) had an unknown tobacco 
history, the information was not stated in the record, not collected, or missing. Of those with 
comorbid conditions collected, 34% (232) were non-Charlson comorbidities and 23% (154) 
were Charlson comorbidities; the remaining 44% (299) had a non-specific code indicating 
the patient had no comorbidities, the information was not known, not collected, or 
comorbidity data was missing in the chart.
Of the 685 patients diagnosed with CML, 55% (374) had a documented BCR-ABL gene test 
recorded by the cancer registry, with 96% (360) of these being positive for the BCR-ABL 
gene. The other 4% (14) of those tested were either negative or the test was ordered but no 
result was recorded. Of the 45% (311) without a test recorded, most (98% [305]) had a flag 
to indicate the test was not done or the test was not applicable; the remaining 2% (6) had 
unknown testing status.
We performed bivariate and multivariable logistic regression analysis to evaluate potential 
factors associated with having a BCR-ABL test ordered (Table 2). As results were similar 
we will only present multivariable logistic regression analysis here (see Table 2 for bivariate 
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results). On initial analysis, one factor, state of residence at diagnosis, stood out as the 
strongest predictor of receiving a BCR-ABL gene test. One state, State A, had significantly 
fewer cases being reported as having had the BCR-ABL gene test compared to the other 
states (24% tested in State A compared to 72% of all the other states combined; range of 
individual states 24%–96%). Discussion with State A cancer registry revealed data 
collection was too resource intensive for staff at the time; therefore state A was removed 
from bivariate and multivariable logistic regression analysis. In addition, tobacco use and 
comorbidity were also excluded because of a high percent of uninterpretable data (33% and 
44% respectfully). Multivariable models included age (as a continuous variable), sex, race/
ethnicity, insurance at diagnosis, census tract poverty and urbanization, and state at 
diagnosis. Age and state of residence remained the only significant factors associated with 
BCR-ABL gene testing in our logistic regression model. Likelihood of BCR-ABL decreased 
with increasing age (OR: 0.97, 95%CI: 0.95–0.99) and residents of states C, D, and E were 
more likely to have BCR-ABL testing compared to state B (state C OR: 20.94, 95%CI: 
4.69–93.51; state D OR: 3.19, 95%CI: 1.16–8.74; state E OR: 3.22, 95%CI: 1.18–8.76).
Tyrosine Kinase Inhibitors use was recorded for 54% (369) of patients (Table 3a); 296 of 
whom also had documented BCR-ABL gene testing. Of the 46% (316) patients not receiving 
TKIs, 77 received other chemotherapy agents (primarily Hydroxyurea) and 239 were 
recoded as no planned chemotherapy (102), unknown if chemotherapy was planned (29), or 
were left blank (108) (data not shown). However, state A reported similar difficulties 
capturing TKI data due to limited resources. Removing State A (Table 3b), resulted in nearly 
78% (305) of the 393 CML patients from states B-J with documented treatment with a TKI. 
The remaining 22% (88) received other chemotherapy (33), no chemotherapy planned (35), 
unknown if received chemotherapy (8), or was left blank (8). We performed bivariate and 
multivariable logistic regression analysis to evaluate factors associated with a patient 
receiving a TKI as part of their first course therapy (Table 4). We again removed the 
variables for comorbidity and tobacco use as well as the data from state A due to missing or 
uninterpretable data. In addition to significant fewer patients being recorded as having 
received a TKI in state A, chemotherapy data was missing all-together in 27% (80) of state 
A CML case reports despite most having a valid date of chemotherapy completed by CoC 
hospitals [RxDateChemo]. State A was also responsible for 66% of those coded as 
“Chemotherapy not planned” and 72% of those coded as “Unknown if chemotherapy 
planned or Not required”. We included age, sex, race/ethnicity, insurance at diagnosis, 
census tract poverty and urbanization, and state at diagnosis in the multivariable logistic 
regression model. Age was used as a continuous variable and remained significantly 
associated (borderline) with receipt of TKI therapy (OR: 0.97, 95%CI: 0.96–0.99).
Discussion
National and international guidelines, including the National Comprehensive Cancer 
Network (NCCN), recommend testing for the BCR-ABL gene to make a definitive diagnosis 
of CML allowing for prompt treatment with a TKI.4, 5, 6 This study attempted to capture 
population based BCR-ABL gene testing for CML patients and guideline therapy with a 
tyrosine kinase inhibitor. Our results show the majority (55%) of patients diagnosed with 
CML were tested by one of four means of genetic testing. However, collected data on testing 
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and treatment varied significantly by state of diagnosis. Based on having a higher percentage 
of missing information, one state appeared to have had a more difficult time collecting 
information on CML diagnosis and treatment. This could be due to less supportive legal 
authority for public health surveillance data collection activities, or may indicate more 
limited health record access or incomplete testing data present in the medical record. States 
also differed by geographic area; total population; number of CoC hospitals; and personnel 
resources, all affecting workload by the associated state registry.
Another possibility was that patients were not being tested appropriately for the BCR-ABL 
gene, resulting in fewer cases eligible for TKI therapy and inaccurate annual rates of CML 
reported. As noted, our study did show nearly 50% of CML cases were diagnosed with CML 
NOS, a diagnosis that should only be used as a temporary placeholder until a definitive 
diagnosis is determined. A recent study by Mertz et.al. also showed high use of CML NOS 
with over 80% of reported CML cases having this diagnosis.20 As a comparison, Höglund 
et.al. evaluated 779 CML cases from 2002–2009 in Sweden and all but 24 had readily 
available BCR-ABL gene testing results through their national registry (would result in a 3% 
use of CML NOS). Also noted by Höglund, Swedish annual rates of CML were lower at 1.0 
case per 100,000 annually compared to SEER 18 annual incidence reports from 2006–2010 
at 1.6 cases per 100,000 per year.21 States included in the NPCR CER study have an annual 
age adjusted rate per 100,000 of 1.8 per year between 2006–2011.17 Inaccurate coding or 
diagnosis, possibly due to incomplete gene testing information, is one possible explanation 
for the rate differences between our countries. This is plausible as cancer registrars may need 
additional training on hematopoietic cancers, especially training related to gene testing. 
However, rate differences between these studies may represent different numerators. For 
example, rates calculated by Höglund included only BCR-ABL+ CML and CML NOS 
cases, but the SEER 18 rates as well as the NPCR- SEER combined U.S. Cancer Statistics 
(USCS) rates are calculated using a CML recode variable that includes not only CML NOS 
and BCR-ABL+ CML cases but also atypical CML (aCML), Chronic Myelomonocytic 
Leukemia (CMML), and Juvenile Myelomonocytic Leukemia (JMML) cases. In their 
analysis of all-cause mortality of patients diagnosed with CML, Brunner et.al. recognized 
that CML cases included in the recode are not all eligible for TKI therapy and would have 
differing overall survival expectation, thus limiting their analysis to BCR-ABL+ CML and 
CML NOS.22 Recalculating rates of CML in CER states using only, CML NOS and BCR-
ABL+ CML results in a decrease to 1.3 per 100,000. Overall national incidence rates for that 
same time period using USCS data were 1.2 per 100,000 per year with 71% coded as CML 
NOS. Although the national rate more closely resembles findings in Europe when limiting 
diagnoses to CML NOS and BCR-ABL+ CML, our high use of CML NOS may include 
non-CML cases classified as such before definitive diagnostic studies were completed.23
Although our CER data are only a snapshot of one diagnosis year, the data showed that a 
slight majority of patients (54%) received a tyrosine kinase inhibitor as part of their first 
course therapy. This percent increases to 78% of patients if data from State A is removed 
from the analysis (State A reported only 21% recorded TKI use). This is similar to what was 
seen in Höglund’s study where it was reported that approximately 85% of CML cases in 
Sweden in 2009 were treated with TKIs within the first year after diagnosis.21 Also 
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consistent with the Swedish study, age was a significant predictor of receiving treatment 
with a TKI as younger patients were more likely to be treated with TKIs than older patients.
Strengths
This study is a multi-state population-based analysis of BCR-ABL testing and treatment for 
CML representing nearly 27% of the United States. Data collected for the NPCR CER study 
included previously uncaptured chemotherapy treatment detail including outpatient 
medications. This study demonstrates complex outpatient diagnostic testing and outpatient 
treatment data can be captured by state registries. However, we have also shown that 
collection of these data can vary significantly between states and is likely multi-factorial. 
The CDC Specialized Registries in this study had not previously collected this level of 
detailed testing and treatment data. It is important to learn from their efforts and continue to 
refine methods of collecting population-based cancer data appropriate for comparative 
effectiveness research and patient centered outcomes research to better describe testing and 
treatments received by patients outside of a clinical trial. Taking advantage of Meaningful 
Use and other Electronic Medical Record utilization to make collecting this type of data 
more economical on a large scale will be important going forward.
Limitations
State and regional cancer registries participating in the NPCR CER project were selected in 
part because of their demographic make-up allowing for a representative sample of the US 
population. However, incomplete data and questionable quality in one state resulted in the 
need to exclude that state from analyses thereby limiting generalizability of our findings. We 
were unable to assess the differences in available testing and treatment data or what factors 
aided the ability of a specific state registry to collect CER data. Possible ways to do this in 
the future would be to review source data, including text fields, for accuracy of data coding. 
Source data may have additional information that would have allowed for the evaluation of 
discordant pairs. These included receiving TKI therapy despite having no BCR-ABL gene 
test performed (Table 3) or not receiving TKI therapy despite having a recorded BCR-ABL+ 
gene test, thus, a candidate for TKIs per guideline recommendation. Additional 
discrepancies were found in diagnostic codes used with those being diagnosed with CML 
NOS despite having a positive BCR-ABL gene test (7%[49]), or being diagnosed with BCR-
ABL + CML despite having the record indicate that the gene testing was not performed or 
not applicable (6%[41], data not shown). Another limitation is our inability to assess the 
phase of disease for individual patients, i.e. chronic, acute, or Blast Crisis. This would 
change treatment options and may place patients on non-TKI medications. However, if a 
patient was not in a clinical trial, treatment should still include a TKI and therefore this was 
a minor limitation.4 Finally the large number of unknown/missing tobacco and comorbidity 
data made it difficult to assess possible health risk factors and health conditions that increase 
the risk of developing CML such as smoking history, or limit TKI use such as those with 
hepatic impairment or congestive heart failure. The NPCR CER Specialized Registries 
reported that tobacco and comorbidity information was not always in the medical record or 
not readily apparent.
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We have shown that collecting detailed testing and treatment information from medical 
records is possible by state cancer registries. In states capable of collecting detailed CML 
data we found a majority of patients had documented BCR-ABL gene testing for definitive 
diagnosis, thus, making them candidates for Tyrosine Kinase Inhibitors. Correspondingly, 
we found a slight majority of patients received guideline concordant care with a TKI. It is 
important to continue efforts to collect population based comparative effectiveness research 
to better describe testing and treatments received by patients outside of a clinical trial. 
Usefulness of data could be improved through complete documentation of test results and 
through careful examination of coding practices to ensure proper diagnosis of CML. 
Additionally, collecting intermediate and long term outcomes at the population level will add 
to our understanding of the efficacy of various therapies. However, we do need further 
research to understand availability of data in different states as well as the need for 
additional training in identifying and coding hematopoietic cancers. The appropriateness of 
separating non-CML leukemias—such as aCML, CMML, and JMML— and CML 
leukemias in national coding schemes needs to be evaluated given the differences in 
treatments and overall survival so that CML statistics can be accurately reported.
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Table 1
Demographic Characteristics for CML Cases Identified as Part of the NPCR CER Dataset, 2011.
N %
Total CML Cases (BCR-ABL+ CML and CML NOS) 685 100.0%
Sex
  Male 376 54.9%
  Female 308 45.0%
  Other (transsexual) 1 0.1%
Age at Diagnosis
  <50 237 34.6%
  50–59 125 18.2%
  60–69 129 18.8%
  ≥70 194 28.3%
Race/Ethnicity
  Non-Hispanic White 440 64.2%
  Non-Hispanic Black 97 14.2%
  Non-Hispanic Other-(AI/AN/AIPI) 14 2.0%
  Hispanic (all races) 126 18.4%
  Other unspecified/Unknown/Missing 8 1.2%
Health Insurance
  Private 282 41.2%
  Insurance NOS 32 4.7%
  Medicaid and other public insurance 90 13.1%
  Medicare 154 22.5%
  No Insurance 68 9.9%
  Unknown/Missing/Blank 59 8.6%
Census Tract Urbanization*
  100% Urban 391 57.1%
  100% Rural 55 8.0%
  Mixed Urban/Rural 235 34.3%
  Missing 4 0.6%
Census Tract Poverty**
  Poverty <20% 555 81.0%
  Poverty ≥20% 126 18.4%
  Blank/Missing 4 0.6%
Tobacco
  Never Used Tobacco Products 273 39.9%
  Current user of Tobacco Products 66 9.6%
  Former user of Tobacco Products 119 17.4%
  Unknown / Missing / Not collected 227 33.1%
Comorbidity
  No Comorbidity / Unknown / Missing / Not collected 299 43.6%
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N %
  At least one NON-Charlson comorbidity 232 33.9%
  At least one Charlson comorbidity 154 22.5%
State of Residence
  State A 292 42.6%
  State B 120 17.5%
  State C 73 10.7%
  State D 64 9.3%
  State E 56 8.2%
  State F 29 4.2%
  State G 20 2.9%
  State H 15 2.2%
  State I 10 1.5%
  State J 6 0.9%
*
Census tracts urbanization defined as urban if 100% of addresses in the census tract are located in an urban setting, 100% rural if 100% of 
addresses in the census tract are located in an urban setting, or mixed
**
Poverty- patient categorized into two categories based on census tract of residence (i.e. where less than 20% of the families in the census tract 
had income below the poverty line in the last 12 months OR 20% or more of households in patient census tract had income below the poverty line 
in the last 12 months)
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Table 2











n= (%*) OR (95% CI) OR (95% CI)
Age at Diagnosis
  <50 116 (84.7%) ref
  50–59 62 (80.5%) 0.748 (0.360–1.554)
  60–69 56 (75.7%) 0.563 (0.278–1.141)
  70–79 71 (67.6%) 0.378 (0.204–0.702)
Age as Continuous 0.971 (0.953–0.990)
Sex
  Male 161 (78.9%) ref ref
  Female 144 (76.6%) 0.874 (0.543–1.408) 0.873 (0.496–1.539
Race/Ethnicity
  Non-Hispanic White 201 (75.6%) ref ref
  Non-Hispanic Black 47 (81.0%) 1.382 (0.677–2.820) 1.054 (0.443–2.510)
  Hispanic 44 (81.5%) 1.423 (0.678–2.986) 1.296 (0.516–3.255)
  Non-Hispanic Other 7 (77.8%) 1.132 (0.229–5.585) 1.456 (0.214–9.900)
  Missing 6
Health Insurance
  Private 148 (82.2%) ref ref
  Insurance NOS 15 (71.4%) 0.540 (0.195–1.500) 0.310 (0.096–1.004)
  Medicaid and other public
insurance 51 (78.5%) 0.788 (0.390–1.593) 0.587 (0.259–1.332)
  Medicare 59 (72.8%) 0.580 (0.312–1.079) 0.682 (0.315–1.481)
  No Insurance 21 (80.8%) 0.908 (0.319–2.589) 0.566 (0.171–1.876)
  Missing 20
Census Tract Residence**
  100% Urban 162 (76.8%) ref ref
  100% Rural 25 (78.1%) 1.080 (0.441–2.649) 1.253 (0.409–3.838)
  Mixed 114 (78.1%) 1.078 (0.650–1.787) 1.832 (0.904–3.713)
  Missing 4
Census Track Poverty***
  Poverty <20% 251 (75.8%) ref ref
  Poverty ≥ 20% 50 (86.2%) 1.992 (0.906–4.379) 1.937 (0.788–4.758)
  Missing 4
State of Residence
  State A [69 (23.6%) BCR-ABL
tested]
  State B 81 (67.5%) ref ref
























n= (%*) OR (95% CI) OR (95% CI)
  State C 70 (95.9%)
11.231 (3.326–
37.925) 20.944 (4.694–93.510)
  State D 53 (82.8%) 2.320 (1.092–4.928) 3.189 (1.163–8.742)
  State E 46 (82.1%) 2.215 (1.012–4.848) 3.215 (1.180–8.760)
  State F 15 (51.7%) 0.516 (0.227–1.174) 0.644 (0.237–1.749)
  State G 17 (85.0%) 2.728 (0.754–9.867) 3.454 (0.885–13.485)
  State H 11 (73.3%) 1.324 (0.396–4.425) 1.539 (0.368–6.433)
  State I 9 (90.0%) 4.333 (0.530–35.422) >999.999 (<0.001–>999.999)
  State J 3 (50.0%) 0.481 (0.093–2.495) 0.088 (0.006–1.393)
*
% of category tested for BCR-ABL gene
**
Census tracts urbanization defined as urban if 100% of addresses in the census tract are located in an urban setting, 100% rural if 100% of 
addresses in the census tract are located in an urban setting, or mixed
***
Poverty- patient categorized into two categories based on census tract of residence (i.e. where less than 20% of the families in the census tract 
had income below the poverty line in the last 12 months OR 20% or more of households in patient census tract had income below the poverty line 
in the last 12 months)
Note: Bolding indicates significant finding
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Table 3
Tyrosine Kinase Inhibitor use by BCR_ABL Test result
a: State A included
Receipt of TKIs (N=685)
BCR_ABL Testing TKI given No TKI given Total
Tested (360 positive) 296 (43.2%) 78 (11.4%) 374 (54.9%)
Not Tested or Unknown 73 (10.7%) 238 (34.7%) 311 (45.4%)
Total 369 (53.9%) 316 (6.7%) 685
b: State A removed
Receipt of TKIs (n=393)
BCR_ABL Testing TKI given No TKI given Total
Tested (360 positive) 267 (67.9%) 41 (10.4%) 308 (78.4%)
Not Tested or Unknown 38 (9.7%) 47 (12.0%) 85 (21.6%)
Total 305 (77.6%) 88 (22.4%) 393
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Table 4











n (%*) OR (95% CI) OR (95% CI)
Age at Diagnosis
  <50 115 (83.9%) ref
  50–59 64 (83.1%) 0.942 (0.445–1.995)
  60–69 59 (79.7%) 0.752 (0.364–1.557)
  70–79 70 (66.7%) 0.383 (0.208–0.704)
Age as Continuous 0.973 (0.957–0.990)
Sex
  Male 159 (77.9%) ref ref
  Female 149 (79.2%) 1.081 (0.667–1.754) 1.106 (0.648–1.886)
Race/Ethnicity
  Non-Hispanic White 206 (77.4%) ref ref
  Non-Hispanic Black 46 (79.3%) 1.117 (0.556–2.242) 1.080 (0.488–2.392)
  Hispanic 44 (81.5%) 1.282 (0.609–2.698) 1.618 (0.652–4.016)
  Non-Hispanic Other 6 (66.7%) 0.583 (0.141–2.399) 0.367 (0.076–1.773)
  Missing 6
Health Insurance
  Private 145 (80.6%) ref ref
  Insurance NOS 16 (76.2%) 0.772 (0.265–2.252) 0.589 (0.190–1.833)
  Medicaid and other public
insurance 50 (76.9%) 0.805 (0.406–1.596) 0.718 (0.338–1.527)
  Medicare 61 (75.3%) 0.736 (0.394–1.376) 1.106 (0.534–2.290)
  No Insurance 23 (88.5%) 1.851 (0.525–6.514) 1.393 (0.357–5.426)
  Missing 20
Census Tract Residence**
  100% Urban 158 (74.9%) ref ref
  100% Rural 28 (87.5%) 2.348 (0.787–7.004) 2.083 (0.616–7.048)
  Mixed 118 (80.8%) 1.414 (0.844–2.369) 1.517 (0.776–2.965)
  Missing 4
Census Track Poverty***
  Poverty <20% 262 (79.2%) ref ref
  Poverty ≥ 20% 42 (72.4%) 0.691 (0.367–1.303) 0.629 (0.304–1.299)
  Missing 4
State of Residence
  State A [61 (21%) TKI therapy]
  State B 96 (80%) ref ref
























n (%*) OR (95% CI) OR (95% CI)
  State C 61 (84%) 1.271 (0.592–2.727) 1.771 (0.759–4.135)
  State D 48 (75%) 0.750 (0.365–1.543) 0.872 (0.342–2.227)
  State E 45 (80%) 1.023 (0.461–2.269) 1.438 (0.541–3.826)
  State F 15 (52%) 0.475 (0.196–1.153) 0.602 (0.215–1.689)
  State G 15 (75%) 0.750 (0.248–2.268) 0.665 (0.208–2.129)
  State H 12 (80%) 1.000 (0.261–3.826) 0.658 (0.157–2.755)
  State I 7 (70%) 0.583 (0.140–2.424) 1.365 (0.232–8.015)
  State J 5 (83%) 1.250 (0.139–11.204) 0.644 (0.054–7.722)
*
% of category tested that received TKI therapy as part of first course therapy
**
Census tracts urbanization defined as urban if 100% of addresses in the census tract are located in an urban setting, 100% rural if 100% of 
addresses in the census tract are located in an urban setting, or mixed
***
Poverty- patient categorized into two categories based on census tract of residence (i.e. where less than 20% of the families in the census tract 
had income below the poverty line in the last 12 months OR 20% or more of households in patient census tract had income below the poverty line 
in the last 12 months)
Note: Bolding indicates significant finding
J Registry Manag. Author manuscript; available in PMC 2017 February 03.
